Oxford BioDynamics PLC, a biotechnology company developing precision medicine tests, has received notice from Vulpes Investment Management Pte Ltd ("Vulpes") regarding a correction to a previous announcement. Vulpes Testudo Fund purchased 443,673 Ordinary Shares of 1 pence each at an average price of 14.75p, rather than the previously announced 343,673 Ordinary Shares at an average price of 14.7p. As a result, Vulpes is currently interested in a total of 28,448,756 shares, representing approximately 14.06% of the Company's current issued share capital. Vulpes is controlled by Non-Executive Director Stephen Diggle, who is deemed to be interested in the same number of shares.
Oxford BioDynamics Plc is a global biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for life-changing diseases. The company's flagship product is EpiSwitch® CiRT, a predictive immune response profile for immuno-oncology checkpoint inhibitor treatments. The company's next commercial product will be the Prostate Screening EpiSwitch® (PSE) blood test, set to be launched in Q4 2023. Oxford BioDynamics has also launched the EpiSwitch® CST, a commercial prognostic test, and the EpiSwitch® Explorer Array Kit, a commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery.
The company has developed a proprietary 3D genomic biomarker platform called EpiSwitch®, which can build molecular diagnostic classifiers for various indications, including response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring. Oxford BioDynamics has partnered with numerous big pharma companies and leading institutions, including Pfizer, Roche, Biogen, and Mayo Clinic. The company's technology portfolio includes biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics, and a curated 3D genome knowledgebase.
Oxford BioDynamics is headquartered in Oxford, UK, and is listed on AIM of the London Stock Exchange. It also has offices in Gaithersburg, USA, and a reference laboratory in Penang, Malaysia. For more information, visit the company's website or follow OBD on Twitter.